Korea Research Institute of Chemical Technology

Hanall Biopharma Co., Ltd.

Korea Research Institute of Bioscience and Biotechnology

Cj Corporation

Jeil Pharm. Co., Ltd.

Sungkyunkwan University

Handok Pharmaceuticals Co., Ltd.

Sang Dal Rhee

Won Hoon Jung

Hyae Gyeong Cheon

Kwang-Rok Kim

Jin Hee Ahn

Ki Young Kim

Sung Wuk Kim

Sung Soo Jun

Seung Kyu Kang

Sung Soo Kim

Jong Cheol Lee

Jeong-Hyung Lee

Sung-eun Yoo

Seung Jun Kim

Jae Mok Lee

Sung Dae Park

Jong Min Kim

Nam Gee Kim

Kwang Rok Kim

Sung-Don Yang

Kwangho Lee

Sung Hoon Ahn

Kyu Yang Yi

Jee Hee Suh

Byung Ho Lee

Gildon Choi

Seok Hee Park

Chong Hak Chae

Jong-Cheol Lee

Nack Jeong Kim

Myung-Ae Bae

Seog Beom Song

Sung Bum Park

Kwang-Seok Oh

Sung Eun Yoo

Myung Ae Bae

Imran Ali

Nam Sook Kang

Jin Sook Song

Mija Ahn

Youn Sook Lee

Soon Ji Kwon

Hi Youn Kim

Sun Mee Kim

Moon Kook Jeon

Jang Hyuk Lee

Hye Jung Kang

Hyun Jung Kwak

Hee Youn Kim

Kil Woong Mo

Koun Ho Lee

Sun Chul Huh

H S Pagire

Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.

Method for preventing, improving, or treating inflammatory bowel disease

Provided herein is a three-dimensional co-culture of adipocytes and macrophages, wherein, in a hydrogel scaffold containing adipocytes and macrophages, the adipocytes and the macrophages are co-cultured to form a fat-like tissue, which can be then utilized in the studies and medicine development for treating metastatic diseases associated with adipose tissue.

Three-dimensional co-culture method for adipocytes and macrophages

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD1), and is useful in the treatment of various diseases that are mediated by 11&#x3b2;-HSD1. 

Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt

Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.

1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same

The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.

N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients

The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.

N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same

The present invention is directed to a novel imidazole derivative having an aryl piperidine substituent of formula (I) and a method for preparation thereof, and a pharmaceutical composition containing said imidazole derivative as an active ingredient for preventing or treating a MCH (melanine-concentrating hormone)-related disease.

Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same

The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

Indene derivatives and process for the preparation thereof

An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, or phenyl; being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH, NO, OR, phenyloxy, Calkyl, and Ccycloalkyl; and

Growing community of inventors

Daejeon, South Korea

Sang Dal Rhee